Advocacy Champion Works to Improve Health Care, Outcomes for Patients With Cancer
August 24th 2021Directions in Oncology Pharmacy is getting to know oncology pharmacy professionals through a series of interviews. In this issue, we talk to Ashley E. Glode, PharmD, BCOP, who was recently named an Advocacy Champion by the American Society of Clinical Oncology (ASCO).
Read More
Study: Physical Activity Associated With Better Cognition in Breast Cancer Patients
August 24th 2021This research lays the foundation for future clinical trials aimed at investigating whether moderate to vigorous exercise can minimize “chemo brain,” which is a decline in cognitive function many patients with breast cancer experience.
Read More
Ongoing Developments and Barriers for Treatment of Alzheimer Disease
August 23rd 2021It is the responsibility of the pharmacist to remain informed of all existing and new drugs for the treatment of Alzheimer disease, especially because novel and investigational drugs may target the pathophysiology of the disease.
Read More
Novel Derivative of Psilocybin May Provide a More Accessible, Effective Form of Treatment for PTSD
August 23rd 2021Col. Dallas Hack, director of medical affairs at MagicMed, discusses the drug development program of a novel derivative of psilocybin for the treatment of post-traumatic stress disorder.
Watch
Study: Cutting 200 Calories Daily, Exercise May Improve Heart Health in Obese Older Adults
August 23rd 2021Additionally, among this population, combining aerobic exercise with a moderate reduction in daily calories resulted in greater improvements in aortic stiffness versus exercise only or exercise plus a more restrictive diet.
Read More
Oncology Reimbursements Must Improve Patient Access, Provide for Overhead Costs
August 20th 2021Kristin Ferguson, DNP, RN, OCN, outlined 4 principles for the reimbursement of oncology drugs, diagnostics, and biomarker testing that were recently released by the Association of Community Cancer Centers.
Watch
FDA Grants Fast Track Designation to STRO-002 for Advanced Ovarian Cancer
August 20th 2021STRO-002 is a folate receptor alpha-targeting antibody drug conjugate for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior lines of systemic therapy.
Read More